ReviewMini reviews in medicinal chemistry2026
Iridoids as Multi-target Neuroprotective Agents for Ischemic Stroke: Mechanisms and Therapeutic Potential.
Review in Mini reviews in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Ischemic stroke continues to be a predominant global cause of death and long-term disability, with therapeutic options remaining notably constrained. Against this challenging backdrop, iridoids-natural monoterpenoids abundantly present in various medicinal plants-have gained significant attention as prospective neuroprotective agents for ischemic stroke. This comprehensive review systematically consolidates preclinical evidence regarding the therapeutic potential of ten representative iridoids, namely catalpol, picroside II, oleuropein, morroniside, loganin, aucubin, geniposide, cornin, gentiopicroside, and swertiamarin, utilizing data from diverse experimental stroke models. Accumulated findings reveal that these iridoid compounds mediate multi-modal neuroprotective benefits primarily through the regulation of crucial pathological cascades, such as excitotoxicity, persistent neuroinflammation, oxidative stress, apoptotic pathways, and blood-brain barrier integrity disruption. From a mechanistic standpoint, iridoids exert their influences by modulating a spectrum of vital signaling pathways, including VEGF/PI3K/Akt, Nrf2/HO-1, NF-κB, MAPK, and Bcl-2. These modulatory activities contribute to enhanced angiogenesis and neurogenesis, facilitate microglial polarization toward the protective M2 phenotype, and effectively mitigate oxidative damage and neuronal apoptosis. Given their pleiotropic mechanisms of action, iridoids constitute a highly promising class of natural scaffolds for developing innovative multi-target therapeutics for ischemic stroke. To advance their translational potential, subsequent research should emphasize structural optimization and synthetic derivatization to improve potency and pharmacokinetics. Concurrently, exploring advanced targeted drug delivery platforms appears imperative to maximize their bioavailability and brain penetration, thereby facilitating the transition of iridoid-based candidates from preclinical research to clinical application.
Indexed as
Identifiers
41879497What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.